Efficacy of glucagon‐like peptide‐1 receptor agonists compared to dipeptidyl peptidase‐4 inhibitors for the management of type 2 diabetes: A meta‐analysis of randomized clinical trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. S1, 2018-02 ,pp. : 68-76

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cardiovascular safety of the glucagon‐like peptide‐1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta‐analysis of randomized controlled trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 5, 2015-05 ,pp. : 505-510

John Wiley & Sons Inc

Access to resources Recommend Favorite

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 974-983

John Wiley & Sons Inc

Access to resources Recommend Favorite

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 974-983

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparative effectiveness of once‐weekly glucagon‐like peptide‐1 receptor agonists with regard to 6‐month glycaemic control and weight outcomes in patients with type 2 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 468-473

John Wiley & Sons Inc

Access to resources Recommend Favorite